Guangzhou, China. November 22, 2022 -- Creative Biosciences (CreativeBio) and Cooper Biosciences MENA (Cooper) - an affiliate of Cooper Pharma Group announced today a partnership for the commercialization of Colosafe® in Morocco, Egypt, Saudi Arabia (KSA) and the United Arab Emirates (UAE). Colosafe® is CreativeBio’s flagship product which is the first NMPA approved stool DNA test kit for colorectal cancer. With the advantages of noninvasive, convenient, accurate and early detection of CRC, Colosafe® has been widely used in hospital, non-hospital, and government organized screening covering 740 medical institutions across the country. By October 2022, Colosafe® has performed over 520,000 testings in China, which has gained tremendous clinical recognition by the professionals and experts.

 

Cooper Pharma is a leading Moroccan pharmaceutical company based in Casablanca since 1933 and operating in Africa and the Middle East. The group is promoting and distributing innovative drugs and diagnostic solutions through its affiliate Cooper Biosciences MENA.

 

”We are very proud to bring Colosafe® to our region which will address an important unmet need. We are confident that this innovative IVD product will play an important role in cancer early detection in the Middle East and North Africa”,commented Ayman Cheikh Lahlou, Chief Executive Officer of Cooper.

 

The partnership will initially launch Colosafe® in Morocco and Saudi Arabia (KSA) using Cooper’s various established commercial channels. Cooper will market Colosafe® and perform testing in laboratories to offer localized service and support.

 

Colosafe® is currently marketed across the Asia Pacific, and the partnership with Cooper marks Colosafe’s initial launch in the Middle East and North Africa (MENA region). Mr. Leo Liao, Senior Vice President of CreativeBio, expect for this cooperation: "I am very pleased to establish this partnership with Cooper, which will be a win-win cooperation for both parties. Based on Cooper's outstanding expertise in the distribution and marketing of pharmaceutical and IVD products, I believe that our best-in-class IVD products will play an important role in improving the clinical practice of cancer screening in the Middle East and North Africa. We hope to save more lives through our long-term partnership."

 

 

About Colosafe®

Full name of Colosafe® is Methylation Detection Kit for Human SDC2 Gene (Real time PCR) & Stool Collection Device which is the first NMPA approved stool DNA test kit for colorectal cancer. Colosafe® entered the special approval channel of National Medical Products Administration in March 2017 and was cleared by NMPA on Nov 20, 2018. It is a product that can precisely detect and interpret the mutated messages (human SDC2 methylation) from stool for detection of colorectal cancer to help physicians to figure out the cancerous lesion early and prevent the development of CRC at early stage. Colosafe® has the advantages of noninvasive, convenient, accurate and early detection of CRC. It has obtained ISO13485 certification and CE mark complying with EU safety, health, and environmental requirements.

 

About Creative Biosciences

Creative Biosciences is an advanced biotech enterprise founded by a team of excellent scientists. Since its registration in January 2015, CreativeBio has been dedicated to the research and development of Colosafe®, an sDNA test for the early detection of colorectal cancer, as well as in manufacturing, sales, and its related automation equipment. The company not only possesses independent intellectual property rights but also boasts its world's top-notch R&D capability which will be improved and transformed into productivity in the future. On top of Colosafe®, other noninvasive early detection kits for lung, bladder, cervical, and liver cancers, together with POCT products have reached amazing development. Guided by the ultimate goal of “Human Health, My Mission”, CreativeBio is striving to make breakthroughs in early diagnosis, early intervention, and prognosis monitoring of chronicle diseases specifically cancer, to benefit all nations.

About Cooper Pharma

Based in Casablanca since 1933, Cooper Pharma is a leading Moroccan pharmaceutical company operating in Africa and the Middle East. Through its affiliates and 9 Manufacturing sites, Cooper Pharma is active in the production and marketing of branded generics and innovative drugs of the highest quality at the best price. The product portfolio of Cooper Pharma has nearly 300 presentations covering the main therapeutic areas: Gastroenterology, Oncology, Cardiology, Dermatology, Rheumatology, Clinics & Hospitals.

Cooper Biosciences MENA is an affiliate company dedicated to the promotion and distribution of innovative Therapeutics and Diagnostics products in the MENA region.